Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. is a biopharmaceutical firm that has both clinical-stage and commercial products. It concentrates on developing cutting-edge therapies across three main health domains: oncology, infectious diseases, and pain management. The company is organized into two primary divisions: Sorrento Therapeutics and Scilex. For cancer treatment, Sorrento employs its unique G-MAB antibody library and advanced delivery systems. These include chimeric antigen receptor T-cell (CAR-T) therapy, dimeric CAR-T, antibody drug conjugates, and bispecific antibodies. Additionally, its Sofusa technology allows for direct lymphatic delivery of biologics. Among its active clinical cancer programs are an anti-CD38 CAR-T therapy for multiple myeloma, amyloidosis, and graft-versus-host disease. In the realm of pain relief, the company is advancing resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin, to address severe cancer pain and osteoarthritis. Its commercial product, ZTlido, is a lidocaine topical system prescribed for post-herpetic neuralgia. The pipeline also includes SEMDEXA, an injectable viscous gel in Phase III trials for sciatica-related low back pain; SP-103, an investigational non-aqueous lidocaine topical system for chronic low back pain; and SP-104, a novel low-dose, delayed-release naltrexone hydrochloride formulation for fibromyalgia. In infectious disease, Sorrento has partnered with SmartPharm Therapeutics Inc. to create a gene-encoded antibody vaccine targeting COVID-19. Furthermore, it collaborates with the Mayo Clinic on a Phase Ib pilot study, evaluating the Sofusa lymphatic drug delivery system for Ipilimumab in melanoma patients. Established in San Diego, California, in 2006, Sorrento Therapeutics, Inc. recently commenced voluntary reorganization under Chapter 11 bankruptcy. This filing, including an affiliate, occurred on February 13, 2023, within the U.S. Bankruptcy Court for the Southern District of Texas.